ISLAMABAD, May 23, 2025 /PRNewswire/ -- In a groundbreaking move to elevate clinical diagnostics nationwide, MindHYVE.ai™, a U.S.-based pioneer in orchestrated agentic AI and swarm-intelligent systems, has signed a formal Memorandum of Understanding (MoU) with Islamabad Diagnostic Centre (IDC). The collaboration will see the deployment of Chiron and Ava-AutoNarrator™—two proprietary, AGI-powered agents—across IDC's core diagnostic workflows.
Initially launching at flagship centers in Islamabad (F-8 Markaz) and Lahore (DHA Phase 4), the pilot will introduce a multi-agent diagnostic intelligence layer, enhancing decision precision, speed, and reproducibility in radiology and laboratory services.
"This isn't just AI—it's agentic intelligence in action," said Belal Faruki, Founder & CEO of MindHYVE.ai™. "By fusing swarm intelligence with domain-specific reasoning models, we're equipping clinicians with AI collaborators that learn, adapt, and elevate patient outcomes—ethically and transparently."
Key Innovations:
- Chiron – A medical diagnostic reasoner, part of MindHYVE.ai™'s Ava-Agent architecture, performs pre-diagnostic inference and real-time anomaly detection across radiological and laboratory datasets.
- Ava-AutoNarrator™ – A semi-autonomous narrative generation agent, trained on clinical ontologies, that synthesizes structured reports aligned with ICD and HL7 standards.
- Agentic Coordination Layer – MindHYVE.ai™'s Swarm AI Framework orchestrates agents in real-time—enabling self-organization, priority optimization, and contextual reasoning across patient records.
- Secure PACS/LIS Integration – Seamless, encrypted integration with IDC's Picture Archiving and Communication Systems (PACS) and Laboratory Information Systems (LIS).
Three-Phase Rollout Strategy:
- Phase 1 – Ground Launch: Initial deployment, radiologist/lab team onboarding, and system calibration.
- Phase 2 – Reasoner Tuning: AGI model refinement, cross-clinic feedback loops, and clinical data harmonization across 5–7 IDC locations.
- Phase 3 – Nationwide Readiness: DRAP-compliant licensing, agent swarm scaling, and full-stack intelligence across IDC's 130+ branches.
Ethical Intelligence Commitment
All systems will be governed under MindHYVE.aiâ„¢'s Ethical AGI Protocol, including:
- Human-in-the-loop validation
- Encrypted patient data pathways
- Collaborative oversight with DRAP and PNAC
- Explainable diagnostic decisions using Ava-Fusionâ„¢ reasoning models
"MindHYVE.aiâ„¢'s orchestrated AGI reflects our vision of scalable, accessible diagnostics," said Dr. Rizwan Uppal, Founder & CEO of IDC. "This alliance ushers in a new era of intelligent healthcare, anchored in ethics and excellence."
About MindHYVE.aiâ„¢
Headquartered in Newport Beach, California, MindHYVE.ai™ builds domain-specific AGI agents, multi-agent orchestration systems, and the Ava-Fusion™ family of reasoning models—driving intelligent transformation in diagnostics, infrastructure, and national systems.
Website: www.mindhyve.ai | Email:hello@mindhyve.ai | Contact: +1 (949) 200-8668
Media Contact
Marc Ortiz
Email: marc.ortiz@mindhyve.ai
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
MindHYVE.ai™ and Islamabad Diagnostic Centre Forge Strategic Alliance to Launch AGI-Powered Diagnostic Intelligence Across Pakistan
MindHYVE.ai™ and Islamabad Diagnostic Centre Forge Strategic Alliance to Launch AGI-Powered Diagnostic Intelligence Across Pakistan
T. Rowe Price Investment Management, Inc. and Braidwell LP participate as new investors
Stephen Williams, MD, Ph.D. joins as Chief Scientific Officer
Rebecca Chambers and Frank Witney, Ph.D. appointed to Board of Directors
FREMONT, Calif., Jan. 12, 2026 /PRNewswire/ -- Alamar Biosciences, Inc. ("Alamar"), a leader in precision proteomics dedicated to advancing the early detection of disease, announced the close of an oversubscribed convertible notes financing, bringing in more than $50 million of new capital. Accounts advised by T. Rowe Price Investment Management, Inc. and Braidwell LP joined the financing as new investors. Existing investors, including Illumina Ventures and Sands Capital, also participated. The financing will support the continued commercial advancement of Alamar's precision proteomics platform.
"We deeply appreciate the continued support from our existing investors and are excited to welcome our new partners," said Dr. Yuling Luo, founder, chairman, and chief executive officer of Alamar. "Their confidence in our vision and strategy underscores the transformative potential of our work. This investment will enable us to accelerate innovation and continue to expand the reach of our platform, unlocking the full value of precision medicine and early disease detection."
Leadership and Board Expansion
Alamar also announced key additions to its executive leadership team and board of directors to support the company's continued growth and commitment to operational excellence.
To further strengthen its scientific leadership, Alamar welcomes Dr. Stephen Williams as Chief Scientific Officer. Steve brings more than three decades of experience in precision medicine and biomarker innovation. He most recently served as Chief Medical Officer at Standard BioTools and SomaLogic, and previously spent 18 years at Pfizer in senior leadership roles. A recognized leader in the scientific community, he has served on the NIH National Advisory Council for Biomedical Imaging and Bioengineering, helped launch the Alzheimer's Disease Neuroimaging Initiative, and co-founded the FDA-FNIH-PhRMA Biomarker Consortium.
Alamar has also appointed Rebecca Chambers and Dr. Frank Witney as directors to its board. Rebecca, Chief Financial Officer at Veracyte, brings deep financial and healthcare leadership experience from her current role as well as previous positions at Outset Medical, Illumina, Myriad Genetics and Life Technologies. Frank, an operating partner at Ampersand Capital Partners, adds over three decades of life sciences leadership experience, including serving as President and CEO of Affymetrix and Dionex Corporation, and currently sits on the boards of Revvity, Cerus Corporation, Standard BioTools, and several private companies.
"I am thrilled to welcome Steve to our leadership team, and Rebecca and Frank to our board of directors," said Dr. Yuling Luo. "Their deep expertise and diverse perspectives will be invaluable as we accelerate our mission to unleash the power of our Precision Proteomics platform, to enable broad impacts across health and disease. This is an exciting moment for Alamar, and we look forward to the impact their leadership will have on driving innovation and growth."
About Alamar Biosciences, Inc.
Alamar Biosciences is a privately held life sciences company dedicated to powering precision proteomics to enable the earliest detection of disease. Leveraging its proprietary NULISA™ technology and the ARGO™ HT System, Alamar's platform is designed to deliver ultra-high sensitivity and addresses key limitations of existing technologies to deliver precision proteomics. For more information, please visit alamarbio.com.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
